Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs ...

A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is ...

Most people infected by the hepatitis C virus (HCV) can be cured with antiviral therapy, but access to the treatment remains limited. Even diagnosis of hepatitis C, a disease that causes chronic ...

Credit: Cepheid. The Xpert HCV test delivers results in about an hour. The Food and Drug Administration (FDA) has granted marketing authorization to Xpert ® HCV, a point-of-care hepatitis C virus (HCV ...

Unlike HIV or HBV, HCV replicates its genome directly into RNA without a DNA intermediate, so it lacks a latent, nuclear form that defies ready immunological clearance. In order for the virus to exist ...

The number of regulatory T cells remains elevated in the peripheral blood of chronic hepatitis C patients, and this increase remains persistent even after the completion of treatment. Analysis of the ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...